Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
President Joe Biden on Monday will sign a sweeping executive order to guide the development of artificial intelligence — requiring industry to develop safety and security standards, introducing new consumer protections and giving federal agencies an extensive to-do list to oversee the rapidly progressing technology.
Beauty tips from Allure Magazine.
A new study finds where millennials live can affect how well they can do.
Apple's latest keynote event will be live-streamed on its website, YouTube and Apple TV At 8 p.m ET.
McDonald's reported better-than-expected profit and sales in the third quarter.
President Joe Biden signed a wide-ranging executive order on artificial intelligence in the U.S.
Stocks jumped in Monday's early session after a slew of earnings and other news events that saw the market attempt to make a positive finish to a rough month. Investors also braced for a rate decision from the Federal Reserve as well as the latest jobs report this week.
Cocoa prices are trading at 44-year highs and global sugar prices are at 12-year highs.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
What to know about open enrollment.
